Baxter International (BAX) 10-Q 7 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	BAX
Entity Registrant Name	BAXTER INTERNATIONAL INC
Entity Central Index Key	10,456
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		544,870,914

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Net sales	$ 2,605	$ 2,585	$ 5,080	$ 4,960
Cost of sales	1,475	1,613	2,908	3,023
Gross margin	1,130	972	2,172	1,937
Marketing and administrative expenses	635	709	1,205	1,350
Research and development expenses	156	195	284	331
Operating income	339	68	683	256
Net interest expense	13	11	27	39
Other expense (income), net	20	(1,161)	22	(4,330)
Income from continuing operations before income taxes	306	1,218	634	4,547
Income tax expense (benefit)	42	6	97	(52)
Income from continuing operations	264	1,212	537	4,599
Income (loss) from discontinued operations, net of tax	1			(7)
Net income	$ 265	$ 1,212	$ 537	$ 4,592
Income from continuing operations per common share
Basic	$ 0.49	$ 2.21	$ 0.99	$ 8.39
Diluted	0.48	2.19	0.97	8.33
Loss from discontinued operations per common share
Basic				(0.01)
Diluted				(0.01)
Net income per common share
Basic	0.49	2.21	0.99	8.38
Diluted	$ 0.48	$ 2.19	$ 0.97	$ 8.32
Weighted-average number of common shares outstanding
Basic	544	548	542	548
Diluted	555	553	553	552
Cash dividends declared per common share	$ 0.160	$ 0.130	$ 0.290	$ 0.245

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 265	$ 1,212	$ 537	$ 4,592
Other comprehensive income (loss), net of tax:
Currency translation adjustments, net of tax expense (benefit) of $28 and ($24) for the three months ended June 30, 2017 and 2016, respectively, and $48 and ($10) for the six months ended June 30, 2017 and 2016, respectively	227	(118)	349	(26)
Pension and other employee benefits, net of tax expense of $10 and $10 for the three months ended June 30, 2017 and 2016, respectively, and $20 and $21 for the six months ended June 30, 2017 and 2016, respectively	17	19	38	40
Hedging activities, net of tax benefit of ($1) and ($2) for the three months ended June 30, 2017 and 2016, respectively, and ($5) and ($5) for the six months ended June 30, 2017 and 2016, respectively	(3)	(5)	(10)	(11)
Available-for-sale securities, net of tax expense of $1 and zero for the three and six months ended June 30, 2017 and 2016, respectively	1	(1,065)	3	(4,431)
Total other comprehensive income (loss), net of tax	242	(1,169)	380	(4,428)
Comprehensive income	$ 507	$ 43	$ 917	$ 164

Condensed Consolidated Stateme4

Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Tax (benefit) expense on currency translation adjustments	$ 28	$ (24)	$ 48	$ (10)
Tax expense on pension and other employee benefits	10	10	20	21
Tax benefit on hedging activities	(1)	(2)	(5)	(5)
Tax expense on available-for-sale securities	$ 1	$ 0	$ 1	$ 0

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash and equivalents	$ 3,817	$ 2,801
Accounts and other current receivables, net	1,721	1,691
Inventories	1,525	1,430
Prepaid expenses and other	619	602
Current assets held for disposition	22	50
Total current assets	7,704	6,574
Property, plant and equipment, net	4,337	4,289
Other assets
Goodwill	2,746	2,595
Other intangible assets, net	1,109	1,111
Other	1,067	977
Total other assets	4,922	4,683
Total assets	16,963	15,546
Current liabilities
Current maturities of long-term debt and lease obligations	3	3
Accounts payable and accrued liabilities	2,471	2,612
Current income taxes payable	83	126
Current liabilities held for disposition	1	3
Total current liabilities	2,558	2,744
Long-term debt and lease obligations	3,454	2,779
Other long-term liabilities	1,786	1,743
Equity
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2017 and 2016	683	683
Common stock in treasury, at cost, 138,913,644 shares in 2017 and 143,890,064 shares in 2016	(7,722)	(7,995)
Additional contributed capital	5,910	5,958
Retained earnings	14,480	14,200
Accumulated other comprehensive (loss) income	(4,176)	(4,556)
Total Baxter shareholders’ equity	9,175	8,290
Noncontrolling interests	(10)	(10)
Total equity	9,165	8,280
Total liabilities and equity	$ 16,963	$ 15,546

Condensed Consolidated Balance6

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value	$ 1	$ 1
Common stock, authorized	2,000,000,000	2,000,000,000
Common stock, issued	683,494,944	683,494,944
Treasury stock, shares	138,913,644	143,890,064

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operations
Net income	$ 537	$ 4,592
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Loss from discontinued operations, net of tax		7
Depreciation and amortization	378	395
Deferred income taxes	(20)	(147)
Stock compensation	46	54
Net periodic pension benefit and OPEB costs	62	60
Net realized gains on the Baxalta Retained Share transactions		(4,387)
Other	45	238
Changes in balance sheet items
Accounts and other current receivables, net	43	(38)
Inventories	(38)	(25)
Accounts payable and accrued liabilities	(112)	(343)
Business optimization and infusion pump payments	(80)	(66)
Other	(94)	61
Cash flows from operations – continuing operations	767	401
Cash flows from operations – discontinued operations	(49)	8
Cash flows from operations	718	409
Cash flows from investing activities
Capital expenditures	(279)	(352)
Acquisitions and investments, net of cash acquired	(36)	(42)
Divestitures and other investing activities, net	2	11
Cash flows from investing activities – continuing operations	(313)	(383)
Cash flows from investing activities – discontinued operations		13
Cash flows from investing activities	(313)	(370)
Cash flows from financing activities
Issuances of debt	633	61
Payments of obligations		(233)
Increase in debt with original maturities of three months or less, net		481
Cash dividends on common stock	(141)	(126)
Proceeds from stock issued under employee benefit plans	200	168
Purchases of treasury stock	(95)
Other	(31)	10
Cash flows from financing activities	566	361
Effect of foreign exchange rate changes on cash and equivalents	45	17
Increase in cash and equivalents	1,016	417
Cash and equivalents at beginning of period	2,801	2,213
Cash and equivalents at end of period	$ 3,817	2,630
Supplemental Schedule of Non-Cash Investing and Financing Activities
Net proceeds on the Baxalta Retained Share transactions		4,387
Payment of obligations in exchange for Baxalta Retained Shares		3,646
Exchange of Baxter shares with Baxalta Retained Shares		$ 611

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (the company or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2016 (2016 Annual Report). In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the interim periods. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the interim period are not necessarily indicative of the results of operations to be expected for the full year. Certain reclassifications have been made to conform the prior period condensed consolidated statements to the current period presentation. Accounting for Venezuelan Operations Currency restrictions enacted in Venezuela require Baxter to obtain approval from the Venezuelan government to exchange Venezuelan bolivars for U.S. dollars and require such exchange to be made at the official exchange rate established by the government. In the first quarter of 2016, the Venezuelan government moved from the three-tier exchange rate system to a two-tiered exchange rate system and the official rate for food and medicine imports was adjusted from 6.3 to 10 bolivars per U.S. dollar. Due to a recent decline in transactions settled at the official rate or the secondary rate and limitations on the company’s ability to repatriate funds generated by its Venezuela operations, the company concluded in the second quarter that it no longer meets the accounting criteria for control over its business in Venezuela and the company deconsolidated its Venezuelan operations on June 30, 2017. As a result of deconsolidating the Venezuelan operations, the company recorded a pre-tax charge of $33 million in other expense (income), net in the second quarter of 2017. This charge included the write-off of the company’s investment in its Venezuelan operations, related unrealized translation adjustments and elimination of intercompany amounts. Beginning in the third quarter of 2017, the company will no longer include the results of its Venezuelan business in its consolidated financial statements. New accounting standards Recently issued accounting standards not yet adopted In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which amends ASC 715, Compensation – Retirement Benefits, to require employers that present a measure of operating income in their statements of earnings to include only the service cost component of net periodic postretirement benefit cost in operating expenses. The service cost component of net periodic postretirement benefit cost should be presented in the same operating expense line items as other employee compensation costs arising from services rendered during the period. The other components of net benefit cost, including interest costs, expected return on assets, amortization of prior service cost/credit, and settlement and curtailment effects, are to be included separately and outside of any subtotal of operating income. The company intends to adopt the standard effective January 1, 2018. This guidance will impact the presentation of the company’s consolidated statements of income with no impact on net income. Upon adoption of the standard on January 1, 2018, operating income for the three and six months ended June 30, 2017, will be recast to increase $8 million and $17 million, respectively, with a corresponding increase in other expense (income), net. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which amends the existing accounting standards for revenue recognition. ASU No. 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. ASU No. 2014-09 will be effective for the company beginning on January 1, 2018. The standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The company has completed an assessment of the new standard and is currently executing its detailed implementation plan and developing processes for gathering information for required disclosures. Based on the work performed to date, the company does not expect the adoption of the new standard to have a material impact on the consolidated financial statements. The company expects to adopt the standard using the modified retrospective method. Recently adopted accounting pronouncements As of January 1, 2017, the company adopted on a prospective basis ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation – Stock Compensation. The updated guidance requires all tax effects related to share-based payments to be recorded in income tax expense in the consolidated statement of income. Previous guidance required that tax effects of deductions in excess of share-based compensation costs (windfall tax benefits) be recorded in additional paid-in capital, and tax deficiencies be recorded in additional paid-in capital to the extent of previously recognized windfall tax benefits, with the remainder recorded in income tax expense. The new guidance also requires the cash flows resulting from windfall tax benefits to be reported as operating activities in the consolidated statement of cash flows, rather than the previous requirement to present windfall tax benefits as an inflow from financing activities and an outflow from operating activities. As a result of the adoption, net income and operating cash flow for the three and six months ended June 30, 2017, increased by approximately $13 million and $30 million, respectively. The prior periods have not been restated and therefore, windfall tax benefits of $12 million and $27 million, respectively, for the three and six months ended June 30, 2016, were not included in net income and were included as an inflow from financing activities and an outflow from operating activities in the condensed consolidated statement of cash flows. In 2016, the company adopted ASU No. 2016-15, Statement of Cash Flows (Topic 230). The guidance requires that the cash payments for debt prepayment or debt extinguishment costs be classified as cash outflows for financing activities. As a result of the adoption, the company recast certain debt repayments and debt extinguishment costs from operating to financing activities which resulted in an increase to operating cash flow and a decrease in financing cash flows of $33 million for the six months ended June 30, 2016. The adoption of this guidance did not impact the company’s condensed consolidated statements of income, condensed consolidated statements of comprehensive income or condensed consolidated balance sheets.

SEPARATION OF BAXALTA INCORPORA

SEPARATION OF BAXALTA INCORPORATED	6 Months Ended
	Jun. 30, 2017
Discontinued Operations And Disposal Groups [Abstract]
SEPARATION OF BAXALTA INCORPORATED	2. SEPARATION OF BAXALTA INCORPORATED On July 1, 2015, Baxter completed the distribution of approximately 80.5% of the outstanding common stock of Baxalta Incorporated (Baxalta) to Baxter shareholders (the Distribution). After giving effect to the Distribution, the company retained 19.5% of the outstanding common stock, or 131,902,719 shares of Baxalta (Retained Shares). The Distribution was made to Baxter’s shareholders of record as of the close of business on June 17, 2015 (Record Date), who received one share of Baxalta common stock for each Baxter common share held as of the Record Date. As a result of the Distribution, Baxalta became an independent public company trading under the symbol “BXLT” on the New York Stock Exchange. On June 3, 2016, Baxalta became a wholly-owned subsidiary of Shire plc (Shire) through a merger of a wholly-owned Shire subsidiary with and into Baxalta, with Baxalta as the surviving subsidiary (the Merger). References in this report to Baxalta prior to the Merger closing date refer to Baxalta as a stand-alone public company. References in this report to Baxalta subsequent to the Merger closing date refer to Baxalta as a subsidiary of Shire. For a portion of Baxalta’s operations, the legal transfer of Baxalta’s assets and liabilities did not occur with the separation of Baxalta on July 1, 2015 due to the time required to transfer marketing authorizations and other regulatory requirements in certain countries. Under the terms of the International Commercial Operations Agreement (ICOA), Baxalta is subject to the risks and entitled to the benefits generated by these operations and assets until legal transfer; therefore, the net economic benefit and any cash collected by these entities by Baxter are transferred to Baxalta. As of June 30, 2017, two countries have not yet been separated. Following is a summary of the operating results of Baxalta, which have been reflected as discontinued operations for the three and six months ended June 30, 2017 and 2016. The assets and liabilities have been classified as held for disposition as of June 30, 2017 and December 31, 2016. Three months ended June 30, Six months ended June 30, (in millions) 2017 2016 2017 2016 Major classes of line items constituting income from discontinued operations before income taxes Net sales $ 2 $ 56 $ 6 $ 120 Cost of sales (1 ) (56 ) (5 ) (115 ) Marketing and administrative expenses — — (1 ) (20 ) Research and development expenses — — — — Other income and expense items that are not major — — — — Income (loss) from discontinued operations before income taxes 1 — — (15 ) Gain on disposal of discontinued operations — — — 17 Income tax expense — — — 9 Income (loss) from discontinued operations, net of tax $ 1 $ — $ — $ (7 ) June 30, December 31, (in millions) 2017 2016 Carrying amounts of major classes of assets included as part of discontinued operations Accounts and other current receivables, net $ 21 $ 48 Property, plant, and equipment, net — 1 Other 1 1 Total assets of the disposal group $ 22 $ 50 Carrying amounts of major classes of liabilities included as part of discontinued operations Accounts payable and accrued liabilities $ 1 $ 3 Total liabilities of the disposal group $ 1 $ 3 As of June 30, 2017 and December 31, 2016, Baxter recorded a liability of $21 million and $47 million, respectively, for its obligation to transfer these net assets to Baxalta. Baxter and Baxalta entered into several agreements in connection with the July 1, 2015 separation, including a transition services agreement (TSA), separation and distribution agreement, manufacturing and supply agreements (MSA), tax matters agreement, an employee matters agreement, a long-term services agreement, and a shareholder’s and registration rights agreement. Pursuant to the TSA, Baxter and Baxalta and their respective subsidiaries are providing to each other, on an interim, transitional basis, various services. Services being provided by Baxter include, among others, finance, information technology, human resources, quality supply chain and certain other administrative services. The services generally commenced on the Distribution date and are expected to terminate within 36 months of the Distribution date. Billings by Baxter under the TSA are recorded as a reduction of the costs to provide the respective service in the applicable expense category, primarily in marketing and administrative expenses, in the condensed consolidated statements of income. In the three and six months ended June 30, 2017, the company recognized approximately $16 million and $36 million, respectively, as a reduction to marketing and administrative expenses related to the TSA. In the three and six months ended June 30, 2016, the company recognized approximately $26 million and $53 million, respectively, as a reduction to marketing and administrative expenses related to the TSA. Pursuant to the MSA, Baxalta or Baxter, as the case may be, manufactures, labels, and packages products for the other party. The terms of the agreements range in initial duration from five to 10 years. In the three and six months ended June 30, 2017, Baxter recognized approximately $6 million and $12 million, respectively, in sales to Baxalta. In the three and six months ended June 30, 2016, Baxter recognized approximately $14 million and $25 million, respectively, in sales to Baxalta. In addition, in the three and six months ended June 30, 2017, Baxter recognized $50 million and $98 million, respectively, in cost of sales related to purchases from Baxalta pursuant to the MSA. In the three and six months ended June 30, 2016, Baxter recognized $48 million and $92 million, respectively, in cost of sales related to purchases from Baxalta pursuant to the MSA. The cash flows associated with these agreements are included in cash flows from operations — continuing operations. Cash outflows of $49 million and inflows of $8 million were reported in cash flows from operations – discontinued operations for the six-month periods ending June 30, 2017 and 2016, respectively. These relate to non-assignable tenders whereby Baxter remains the seller of Baxalta products, transactions related to importation services Baxter provides in certain countries, in addition to trade payables settled post local separation on Baxalta’s behalf.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
SUPPLEMENTAL FINANCIAL INFORMATION	3. SUPPLEMENTAL FINANCIAL INFORMATION Net interest expense Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Interest expense, net of capitalized interest $ 21 $ 16 $ 40 $ 49 Interest income (8 ) (5 ) (13 ) (10 ) Net interest expense $ 13 $ 11 $ 27 $ 39 Other expense (income), net Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Foreign exchange $ (15 ) $ (3 ) $ (15 ) $ (12 ) Net loss on debt extinguishment — — — 101 Net realized gains on Baxalta Retained Shares transactions — (1,148 ) — (4,387 ) Venezuela deconsolidation 33 — 33 — All other 2 (10 ) 4 (32 ) Other expense (income), net $ 20 $ (1,161 ) $ 22 $ (4,330 ) Inventories June 30, December 31, (in millions) 2017 2016 Raw materials $ 329 $ 319 Work in process 141 122 Finished goods 1,055 989 Inventories $ 1,525 $ 1,430 Property, plant and equipment, net June 30, December 31, (in millions) 2017 2016 Property, plant and equipment, at cost $ 9,592 $ 9,162 Accumulated depreciation (5,255 ) (4,873 ) Property, plant and equipment, net $ 4,337 $ 4,289

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
EARNINGS PER SHARE	4. EARNINGS PER SHARE The numerator for both basic and diluted earnings per share (EPS) is either net income, income from continuing operations, or income from discontinued operations. The denominator for basic EPS is the weighted-average number of common shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units (RSUs) and performance share units (PSUs) is reflected in the denominator for diluted EPS using the treasury stock method. The following table is a reconciliation of basic shares to diluted shares. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Basic shares 544 548 542 548 Effect of dilutive securities 11 5 11 4 Diluted shares 555 553 553 552 The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excluded 6 million and 4 million equity awards for the second quarter and six months ended June 30, 2017, respectively, and 9 million and 14 million equity awards for the second quarter and six months ended June 30, 2016, because their inclusion would have had an anti-dilutive effect on diluted EPS. Refer to Note 9 for additional information regarding items impacting basic shares. Stock repurchases In July 2012, the Board of Directors authorized the repurchase of up to $2 billion of the company’s common stock. The board of directors increased this authority by an additional $1.5 billion in November 2016. During the first half of 2017, the company repurchased 1.8 million shares for $95 million in cash. During the first half of 2016, the company did not repurchase any shares. The company has $1.6 billion remaining available under the authorization as of June 30, 2017.

ACQUISITIONS AND OTHER ARRANGEM

ACQUISITIONS AND OTHER ARRANGEMENTS	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
ACQUISITIONS AND OTHER ARRANGEMENTS	5. ACQUISITIONS AND OTHER ARRANGEMENTS Celerity Pharmaceuticals, LLC In the second quarter of 2017, Baxter paid approximately $10 million to acquire the rights to Clindamycin Saline from Celerity Pharmaceuticals, LLC (Celerity). Baxter capitalized the purchase price as an intangible asset and is amortizing the asset over the estimated economic life of 12 years. In the first quarter of 2016, Baxter paid approximately $23 million to acquire the rights to Vancomycin injection in 0.9% Sodium Chloride (Normal Saline) in 500mg, 750mg, and 1 gram presentations from Celerity. Baxter capitalized the purchase price as an intangible asset and is amortizing the asset over the estimated economic life of 12 years. Refer to Note 5 within the 2016 Annual Report for additional information regarding the company’s agreement with Celerity. Wound Care Technologies, Inc. In April 2017, Baxter paid approximately $8 million to acquire Wound Care Technologies, Inc., a medical technology company that develops and markets external tissue expansion devices for the wound care market. The purchase price allocation resulted in an amortizable intangible asset of $8 million that will be amortized over its estimated economic life of 8 years.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS, NET	6 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS, NET	6. GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The following is a reconciliation of goodwill by business segment. (in millions) Renal Hospital Products Total Balance as of December 31, 2016 $ 397 $ 2,198 $ 2,595 Additions 5 2 7 Currency translation adjustments 22 122 144 Balance as of June 30, 2017 $ 424 $ 2,322 $ 2,746 As of June 30, 2017, there were no accumulated goodwill impairment losses. Other intangible assets, net The following is a summary of the company’s other intangible assets. (in millions) Developed technology, including patents Other amortized intangible assets Indefinite-lived intangible assets Total June 30, 2017 Gross other intangible assets $ 1,802 $ 408 $ 32 $ 2,242 Accumulated amortization (940 ) (193 ) — (1,133 ) Other intangible assets, net $ 862 $ 215 $ 32 $ 1,109 December 31, 2016 Gross other intangible assets $ 1,690 $ 384 $ 57 $ 2,131 Accumulated amortization (855 ) (165 ) — (1,020 ) Other intangible assets, net $ 835 $ 219 $ 57 $ 1,111 Intangible asset amortization expense was $36 million and $42 million in the three months ended June 30, 2017 and 2016, respectively, and $74 million and $82 million in the six months ended June 30, 2017 and 2016, respectively. In the second quarter of 2016, the company recorded an impairment charge of $51 million, of which $41 million related to a developed technology asset, relating to the company’s Hospital Products segment synthetic bone repair products business which was acquired from ApaTech Limited in 2010. The assets of the business were written down to estimated fair value and recorded in cost of sales.

BUSINESS OPTIMIZATION CHARGES

BUSINESS OPTIMIZATION CHARGES	6 Months Ended
	Jun. 30, 2017
Restructuring And Related Activities [Abstract]
BUSINESS OPTIMIZATION CHARGES	7. BUSINESS OPTIMIZATION CHARGES Beginning in the second half of 2015, the company initiated actions to transform its cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. Through June 30, 2017, the company has incurred cumulative pretax costs of $474 million related to these actions. The costs consisted primarily of employee termination, implementation costs and accelerated depreciation. The company expects to incur additional pretax costs of approximately $335 million and capital expenditures of $90 million through the completion of these initiatives by the end of 2018. The costs will primarily include employee termination costs, implementation costs, and accelerated depreciation. Of this amount, the company expects that approximately 5 percent of the charges will be non-cash. During the three and six months ended June 30, 2017 and 2016, the company recorded the following charges related to business optimization programs. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Restructuring charges, net $ 16 $ 103 $ 19 $ 107 Costs to implement business optimization programs 16 15 37 19 Gambro integration costs — 7 — 14 Accelerated depreciation 3 14 8 14 Total business optimization charges $ 35 $ 139 $ 64 $ 154 During the three and six months ended June 30, 2017 and 2016, the company recorded the following restructuring charges. Three months ended June 30, 2017 (in millions) COGS SGA R&D Total Employee termination costs $ 4 $ 3 $ — $ 7 Contract termination costs — 4 — 4 Asset impairments 5 — — 5 Total restructuring charges $ 9 $ 7 $ — $ 16 Three months ended June 30, 2016 (in millions) COGS SGA R&D Total Employee termination costs $ 18 $ 9 $ 13 $ 40 Contract termination costs 12 2 14 28 Asset impairments 22 — 13 35 Total restructuring charges $ 52 $ 11 $ 40 $ 103 Six months ended June 30, 2017 (in millions) COGS SGA R&D Total Employee termination costs $ 14 $ 9 $ — $ 23 Contract termination costs — 5 — 5 Asset impairments 5 — — 5 Reserve adjustments (7 ) (5 ) (2 ) (14 ) Total restructuring charges $ 12 $ 9 $ (2 ) $ 19 Six months ended June 30, 2016 (in millions) COGS SGA R&D Total Employee termination costs $ 31 $ 10 $ 14 $ 55 Contract termination costs 12 2 14 28 Asset impairments 22 — 13 35 Reserve adjustments (1 ) (8 ) (2 ) (11 ) Total restructuring charges $ 64 $ 4 $ 39 $ 107 Costs to implement business optimization programs for the three and six months ended June 30, 2017, were $16 million and $37 million respectively, and consisted primarily of external consulting and transition costs as well as employee salary and related costs. These costs were included within cost of sales and marketing and administrative expense. Costs to implement business optimization programs for the three and six months ended June 30, 2016, were $15 million and $19 million, respectively, and were related primarily to external consulting costs. These costs were included within marketing and administrative and R&D expense. Costs related to the integration of Gambro AB (Gambro) were included within marketing and administrative expense for all referenced periods. For the three and six months ended June 30, 2017, the company recognized accelerated depreciation, primarily associated with facilities to be closed, of $3 million and $8 million respectively. The costs were recorded within cost of sales, marketing and administrative and R&D expense. For the three and six months ended June 30, 2016, the company recognized $14 million of accelerated depreciation, primarily associated with facilities to be closed. The costs were recorded in cost of sales for all referenced periods. The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives. (in millions) Reserves as of December 31, 2016 $ 164 Charges 28 Reserve adjustments (14 ) Utilization (80 ) CTA 14 Reserves as of June 30, 2017 $ 112 Reserve adjustments primarily relate to employee termination cost reserves established in prior periods. Approximately 80% of the company’s restructuring reserves as of June 30, 2017 relate to employee termination costs, with the remaining reserves attributable to contract termination costs. The reserves are expected to be substantially utilized by the end of 2018.

DEBT, FINANCIAL INSTRUMENTS AND

DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2017
Debt Financial Instruments And Fair Value Measurements [Abstract]
DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	8. DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Debt Issuance In May 2017, Baxter issued senior notes with a total aggregate principal amount of €600 million at a fixed coupon rate of 1.30% due in May 2025. The company has designated this debt as a non-derivative net investment hedge of its European operations for accounting purposes. Debt-for-equity exchanges On January 27, 2016, Baxter exchanged Baxalta Retained Shares for the extinguishment of $1.45 billion aggregate principal amount outstanding under its $1.8 billion U.S. dollar-denominated revolving credit facility. This exchange extinguished the indebtedness under the facility, which was terminated in connection with such debt-for-equity exchange. There were no material prepayment penalties or breakage costs associated with the termination of the facility. Baxter recognized a net realized gain of $1.25 billion related to the Baxalta Retained Shares exchanged, which was included in other expense (income), net for the period ended June 30, 2016. On March 16, 2016, the company exchanged Baxalta Retained Shares for the extinguishment of approximately $2.2 billion in principal amount of its 0.950% Notes due May 2016, 5.900% Notes due August 2016, 1.850% Notes due January 2017, 5.375% Notes due May 2018, 1.850% Notes due June 2018, 4.500% Notes due August 2019, and 4.250% Notes due February 2020 purchased by certain third party purchasers in the previously announced debt tender offers. As a result, the company recognized a net loss on extinguishment of debt totaling $101 million and a net realized gain of $2.0 billion on the Baxalta Retained Shares exchanged, which are included in other expense (income), net for the period ended June 30, 2016. Securitization arrangement The following is a summary of the activity relating to the company’s securitization arrangement in Japan. Three months ended June 30, Six months ended June 30, (in millions) 2017 2016 2017 2016 Sold receivables at beginning of period $ 61 $ 85 $ 68 $ 81 Proceeds from sales of receivables 67 93 129 197 Cash collections (remitted to the owners of the receivables) (66 ) (121 ) (137 ) (228 ) Effect of currency exchange rate changes 1 5 3 12 Sold receivables at end of period $ 63 $ 62 $ 63 $ 62 The impacts on the condensed consolidated statements of income relating to the sale of receivables were immaterial for each period. Refer to the 2016 Annual Report for further information regarding the company’s securitization agreements. Concentrations of credit risk The company invests excess cash in certificates of deposit or money market funds and diversifies the concentration of cash among different financial institutions. With respect to financial instruments, where appropriate, the company has diversified its selection of counterparties, and has arranged collateralization and master-netting agreements to minimize the risk of loss. The company continues to do business with foreign governments in certain countries, including Greece, Spain, Portugal and Italy that have experienced a deterioration in credit and economic conditions. As of June 30, 2017, the company’s net accounts receivable from the public sector in Greece, Spain, Portugal and Italy totaled $148 million. Global economic conditions and liquidity issues in certain countries have resulted, and may continue to result, in delays in the collection of receivables and credit losses. Governmental actions and customer-specific factors may also require the company to re-evaluate the collectability of its receivables and the company could potentially incur additional credit losses. These conditions may also impact the stability of the Euro. Derivatives and hedging activities The company operates on a global basis and is exposed to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. The company’s hedging policy attempts to manage these risks to an acceptable level based on the company’s judgment of the appropriate trade-off between risk, opportunity and costs. The company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Chinese Yuan, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso and New Zealand Dollar. The company manages its foreign currency exposures on a consolidated basis, which allows the company to net exposures and take advantage of any natural offsets. In addition, the company uses derivative and nonderivative instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from foreign exchange. Financial market and currency volatility may limit the company’s ability to cost-effectively hedge these exposures. The company is also exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in interest rates. The company’s policy is to manage interest costs using a mix of fixed- and floating-rate debt that the company believes is appropriate. To manage this mix in a cost-efficient manner, the company periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. The company does not hold any instruments for trading purposes and none of the company’s outstanding derivative instruments contain credit-risk-related contingent features. All derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. Based upon the exposure being hedged, the company designates its hedging instruments as cash flow, fair value, or net investment hedges. Cash Flow Hedges The company may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is accumulated in accumulated other comprehensive income (AOCI) and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in net sales, cost of sales, net interest expense, and other expense (income), net, and primarily relate to forecasted third-party sales denominated in foreign currencies, forecasted intercompany sales denominated in foreign currencies, and anticipated issuances of debt, respectively. The notional amounts of foreign exchange contracts were $673 million and $561 million as of June 30, 2017 and December 31, 2016, respectively. There were no outstanding interest rate contracts designated as cash flow hedges as of June 30, 2017 and December 31, 2016. The maximum term over which the company has cash flow hedge contracts in place related to forecasted transactions as of June 30, 2017 is 17 months. Fair Value Hedges The company uses interest rate swaps to convert a portion of its fixed-rate debt into variable-rate debt. These instruments hedge the company’s earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in net interest expense, as they hedge the interest rate risk associated with certain of the company’s fixed-rate debt. The total notional amount of interest rate contracts designated as fair value hedges was $200 million as of June 30, 2017 and December 31, 2016 Net Investment Hedges In May 2017, the company issued €600 million of senior notes due May 2025. The company has designated this debt as a hedge of a portion of its net investment in its European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances have been and will be recorded as a component of AOCI. As of June 30, 2017, the company had accumulated pre-tax unrealized translation losses in AOCI of $31 million related to the Euro-denominated senior notes. Dedesignations If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If the company removes the cash flow hedge designation because the hedged forecasted transactions are no longer probable of occurring, any gains or losses are immediately reclassified from AOCI to earnings. Gains or losses relating to terminations of effective cash flow hedges in which the forecasted transactions are still probable of occurring are deferred and recognized consistent with the loss or income recognition of the underlying hedged items. There were no hedge dedesignations in the first six months of 2017 or 2016 resulting from changes in the company’s assessment of the probability that the hedged forecasted transactions would occur. If the company terminates a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged items at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first six months of 2017. In March 2016, the company terminated a total notional value of $765 million of interest rate contracts in connection with the March debt tender offers, resulting in a $34 million reduction to the debt extinguishment loss. Undesignated Derivative Instruments The company uses forward contracts to hedge earnings from the effects of foreign exchange relating to certain of the company’s intercompany and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges, and the change in fair value, which substantially offsets the change in book value of the hedged items, is recorded directly to other expense (income), net. The terms of these instruments generally do not exceed one month. The total notional amount of undesignated derivative instruments was $756 million as of June 30, 2017 and $822 million as of December 31, 2016. Gains and Losses on Hedging Activities The following tables summarize the income statement locations and gains and losses on the company’s derivative instruments for the three months ended June 30, 2017 and 2016. Gain (loss) recognized in OCI Location of gain (loss) Gain (loss) reclassified from AOCI into income (in millions) 2017 2016 in income statement 2017 2016 Cash flow hedges Interest rate contracts $ (3 ) $ — Net interest expense $ — $ — Foreign exchange contracts (5 ) (7 ) Cost of sales (3 ) (2 ) Net investment hedge (31 ) — Other expense (income), net — — Total $ (39 ) $ (7 ) $ (3 ) $ (2 ) Gain (loss) recognized in income (in millions) Location of gain (loss) in income statement 2017 2016 Fair value hedges Interest rate contracts Net interest expense $ 1 $ 4 Undesignated derivative instruments Foreign exchange contracts Other expense (income), net $ (4 ) $ (11 ) The following tables summarize the income statement locations and gains and losses on the company’s derivative instruments for the six months ended June 30, 2017 and 2016. Gain (loss) recognized in OCI Location of gain (loss) Gain (loss) reclassified from AOCI into income (in millions) 2017 2016 in income statement 2017 2016 Cash flow hedges Interest rate contracts $ (3 ) $ — Other expense (income), net $ — $ 4 Foreign exchange contracts (13 ) (11 ) Cost of sales (1 ) (1 ) Net investment hedge (31 ) — Other expense (income), net — — Total $ (47 ) $ (11 ) $ (1 ) $ 3 Gain (loss) recognized in income (in millions) Location of gain (loss) in income statement 2017 2016 Fair value hedges Interest rate contracts Net interest expense $ — $ 26 Undesignated derivative instruments Foreign exchange contracts Other expense (income), net $ (4 ) $ (5 ) For the company’s fair value hedges, equal and offsetting losses of $1 million were recognized in net interest expense in the second quarter of 2017 and equal and offsetting losses of $4 million and $26 million were recognized in net interest expense in the second quarter and first half of 2016, respectively, as adjustments to the underlying hedged item, fixed-rate debt. Ineffectiveness related to the company’s cash flow and fair value hedges for all periods presented were not material. As of June 30, 2017, $5 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. Fair Values of Derivative Instruments The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of June 30, 2017. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other long-term assets $ 7 Other long- term liabilities $ — Foreign exchange contracts Prepaid expenses and other 11 Accounts payable and accrued liabilities 1 Foreign exchange contracts Other long-term assets 3 Other long- term liabilities — Total derivative instruments designated as hedges $ 21 $ 1 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other $ — Accounts payable and accrued liabilities $ 1 Total derivative instruments $ 21 $ 2 The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2016. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other long-term assets $ 7 Other long- term liabilities $ — Foreign exchange contracts Prepaid expenses and other 22 Accounts payable and accrued liabilities 1 Total derivative instruments designated as hedges $ 29 $ 1 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other $ 1 Accounts payable and accrued liabilities $ 2 Total derivative instruments $ 30 $ 3 While the company’s derivatives are all subject to master netting arrangements, the company presents its assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, the company is not required to post collateral for any of its outstanding derivatives. The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty. June 30, 2017 December 31, 2016 (in millions) Asset Liability Asset Liability Gross amounts recognized in the consolidated balance sheet $ 21 $ 2 $ 30 $ 3 Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet (2 ) (2 ) (3 ) (3 ) Total $ 19 $ — $ 27 $ — Fair value measurements The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheets. Basis of fair value measurement (in millions) Balance as of June 30, 2017 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Foreign currency hedges $ 14 $ — $ 14 $ — Interest rate hedges 7 — 7 — Available-for-sale securities 10 10 — — Total assets $ 31 $ 10 $ 21 $ — Liabilities Foreign currency hedges $ 2 $ — $ 2 $ — Contingent payments related to acquisitions 10 — — 10 Total liabilities $ 12 $ — $ 2 $ 10 Basis of fair value measurement (in millions) Balance as of December 31, 2016 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Foreign currency hedges $ 23 $ — $ 23 $ — Interest rate hedges 7 — 7 — Available-for-sale securities 9 9 — — Total assets $ 39 $ 9 $ 30 $ — Liabilities Foreign currency hedges $ 3 $ — $ 3 $ — Contingent payments related to acquisitions 19 — — 19 Total liabilities $ 22 $ — $ 3 $ 19 As of June 30, 2017, cash and equivalents of $3.8 billion included money market funds of approximately $1 billion, and as of December 31, 2016, cash and equivalents of $2.8 billion included money market funds of approximately $1 billion. Money market funds would be considered Level 2 in the fair value hierarchy. For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by the company are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs are considered observable and vary depending on the type of derivative, and include contractual terms, interest rate yield curves, foreign exchange rates and volatility. Contingent payments related to acquisitions consist of commercial milestone payments and sales-based payments, and are valued using discounted cash flow techniques. The fair value of commercial milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or expectation of timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increase or expectation of timing of payment is accelerated. The change in the fair value of contingent payments related to Baxter’s acquisitions, which use significant unobservable inputs (Level 3) in the fair value measurement, were primarily driven by payments of approximately $8 million in the first half of 2017. The following table provides information relating to the company’s investments in available-for-sale equity securities. (in millions) Amortized cost Unrealized gains Unrealized losses Fair value June 30, 2017 $ 9 $ 2 $ 1 $ 10 December 31, 2016 $ 13 $ — $ 4 $ 9 In the first quarter of 2017, the company recorded a net $4 million other-than-temporary impairment charges within other expense (income), net based on the duration of losses related to one of the company’s investments. In the second quarter and first six months of 2016 the company recorded $1.1 billion and $4.4 billion, respectively, of net realized gains within other expense (income), net related to exchanges of available-for-sale equity securities, which represented gains from the Retained Share transactions. Book Values and Fair Values of Financial Instruments In addition to the financial instruments that the company is required to recognize at fair value in the condensed consolidated balance sheets, the company has certain financial instruments that are recognized at historical cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the approximate fair values as of June 30, 2017 and December 31, 2016. Book values Approximate fair values (in millions) 2017 2016 2017 2016 Assets Investments $ 41 $ 31 $ 41 $ 31 Liabilities Current maturities of long-term debt and lease obligations $ 3 $ 3 $ 3 $ 3 Long-term debt and lease obligations 3,454 2,779 3,494 2,756 The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of June 30, 2017 and December 31, 2016. Basis of fair value measurement (in millions) Balance as of June 30, 2017 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Investments $ 41 $ — $ — $ 41 Total assets $ 41 $ — $ — $ 41 Liabilities Current maturities of long-term debt and lease obligations $ 3 $ — $ 3 $ — Long-term debt and lease obligations 3,494 — 3,494 — Total liabilities $ 3,497 $ — $ 3,497 $ — Basis of fair value measurement (in millions) Balance as of December 31, 2016 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Investments $ 31 $ — $ — $ 31 Total assets $ 31 $ — $ — $ 31 Liabilities Current maturities of long-term debt and lease obligations $ 3 $ — $ 3 $ — Long-term debt and lease obligations 2,756 — 2,756 — Total liabilities $ 2,759 $ — $ 2,759 $ — Investments in 2017 and 2016 included certain cost method investments. In determining the fair value of cost method investments, the company takes into consideration recent transactions, as well as the financial information of the investee, which represents a Level 3 basis of fair value measurement. The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instrument. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with the company’s credit risk. The carrying values of the other financial instruments approximate their fair values due to the short-term maturities of most of these assets and liabilities.

STOCK COMPENSATION

STOCK COMPENSATION	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
STOCK COMPENSATION	9. STOCK COMPENSATION Stock compensation expense totaled $28 million and $32 million in the second quarter of 2017 and 2016, respectively, and $46 million and $54 million for the six months ended June 30, 2017 and 2016, respectively. Approximately 70% of stock compensation expense is classified in marketing and administrative expenses with the remainder classified in cost of sales and R&D expenses. In March 2017, the company awarded its annual stock compensation grants which consisted of 5.4 million stock options, 0.7 million RSUs and 0.6 million PSUs.

RETIREMENT AND OTHER BENEFIT PR

RETIREMENT AND OTHER BENEFIT PROGRAMS	6 Months Ended
	Jun. 30, 2017
Compensation And Retirement Disclosure [Abstract]
RETIREMENT AND OTHER BENEFIT PROGRAMS	10. RETIREMENT AND OTHER BENEFIT PROGRAMS The following is a summary of net periodic benefit cost relating to the company’s pension and other postemployment benefit (OPEB) plans. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Pension benefits Service cost $ 23 $ 24 $ 45 $ 47 Interest cost 45 46 90 92 Expected return on plan assets (73 ) (76 ) (145 ) (151 ) Amortization of net losses and other deferred amounts 41 38 81 75 Net periodic pension benefit cost $ 36 $ 32 $ 71 $ 63 OPEB Service cost $ — $ 1 $ — $ 2 Interest cost 2 2 4 4 Amortization of net loss and prior service credit (7 ) (4 ) (13 ) (8 ) Net periodic OPEB cost $ (5 ) $ (1 ) $ (9 ) $ (2 )

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	11. ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive income includes all changes in shareholders’ equity that do not arise from transactions with shareholders, and consists of net income, CTA, pension and other employee benefits, unrealized gains and losses on cash flow hedges and unrealized gains and losses on available-for-sale equity securities. The following table is a net-of-tax summary of the changes in AOCI by component for the six months ended June 30, 2017 and 2016. (in millions) CTA Pension and other employee benefits Hedging activities Available- for-sale securities Total Gains (losses) Balance as of December 31, 2016 $ (3,438 ) $ (1,161 ) $ 3 $ 40 $ (4,556 ) Other comprehensive income before reclassifications 320 (8 ) (11 ) — 301 Amounts reclassified from AOCI (a) 29 46 1 3 79 Net other comprehensive income (loss) 349 38 (10 ) 3 380 Balance as of June 30, 2017 $ (3,089 ) $ (1,123 ) $ (7 ) $ 43 $ (4,176 ) (in millions) CTA Pension and other employee benefits Hedging activities Available- for-sale- securities Total Gains (losses) Balance as of December 31, 2015 $ (3,191 ) $ (1,064 ) $ 7 $ 4,472 $ 224 Other comprehensive income before reclassifications (26 ) (7 ) (9 ) 105 63 Amounts reclassified from AOCI (a) — 47 (2 ) (4,536 ) (4,491 ) Net other comprehensive income (loss) (26 ) 40 (11 ) (4,431 ) (4,428 ) Balance as of June 30, 2016 $ (3,217 ) $ (1,024 ) $ (4 ) $ 41 $ (4,204 ) (a) See table below for details about these reclassifications. The following is a summary of the amounts reclassified from AOCI to net income during the three and six months ended June 30, 2017 and 2016. Amounts reclassified from AOCI (a) (in millions) Three months ended June 30, 2017 Six months ended June 30, 2017 Location of impact in income statement Translation adjustments Loss on Venezuela deconsolidation $ (29 ) $ (29 ) Other expense (income), net (29 ) (29 ) Total before tax — — Tax expense $ (29 ) $ (29 ) Net of tax Amortization of pension and other employee benefits items Actuarial losses and other (b) $ (34 ) $ (68 ) (34 ) (68 ) Total before tax 11 22 Tax benefit $ (23 ) $ (46 ) Net of tax Losses on hedging activities Foreign exchange contracts $ (3 ) $ (1 ) Cost of sales (3 ) (1 ) Total before tax 1 — Tax benefit $ (2 ) $ (1 ) Net of tax Available-for-sale-securities Other-than-temporary impairment of equity securities $ — $ (4 ) Other expense (income), net — (4 ) Total before tax — 1 Tax benefit — (3 ) Net of tax Total reclassification for the period $ (54 ) $ (79 ) Total net of tax Amounts reclassified from AOCI (a) (in millions) Three months ended June 30, 2016 Six months ended June 30, 2016 Location of impact in income statement Amortization of pension and other employee benefits items Actuarial losses and other (b) $ (34 ) $ (67 ) (34 ) (67 ) Total before tax 9 20 Tax benefit $ (25 ) $ (47 ) Net of tax Gains (losses) on hedging activities Interest rate contracts $ — $ 4 Other expense (income), net Foreign exchange contracts (2 ) (1 ) Cost of sales (2 ) 3 Total before tax 1 (1 ) Tax benefit (expense) $ (1 ) $ 2 Net of tax Available-for-sale-securities Gains on sale of equity securities $ 1,148 $ 4,536 Other expense (income), net 1,148 4,536 Total before tax — — Tax expense 1,148 4,536 Net of tax Total reclassification for the period $ 1,122 $ 4,491 Total net of tax (a) Amounts in parentheses indicate reductions to net income. (b) These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 10. Refer to Note 8 for additional information regarding hedging activity and Note 10 for additional information regarding the amortization of pension and other employee benefits items.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	12. INCOME TAXES Effective tax rate The company’s effective income tax rate for continuing operations was 13.7% and 0.5% in the second quarters of 2017 and 2016, respectively, and 15.3% and (1.1%) in the six months ended June 30, 2017 and 2016, respectively. The company’s effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. In addition, the effective tax rate can be impacted each period by discrete factors and events. The effective income tax rate for continuing operations increased during the six months ended June 30, 2017 principally due to the absence of the tax-free net realized gains associated with the Baxalta Retained Share transactions, which included debt-for-equity exchanges, the contribution of Baxalta Retained Shares to the company’s U.S. pension plan and the exchange of Baxalta Retained Shares for shares of the company, as well as benefits attributable to closing an IRS and German income tax audit that were all reflected during the six months ended June 30, 2016. The effective income tax rate for continuing operations during the six months ended June 30, 2017 was favorably impacted by approximately 4.7 percentage points due to tax windfall benefits realized from stock option exercises and vesting of RSUs and PSUs associated with the company’s stock compensation programs.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	13. LEGAL PROCEEDINGS Baxter is involved in product liability, patent, commercial, and other legal matters that arise in the normal course of the company’s business. The company records a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is recorded. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of June 30, 2017, the company’s total recorded reserves with respect to legal matters were $19 million and there were no related receivables. Baxter has established reserves for certain of the matters discussed below. The company is not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While the liability of the company in connection with the claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on the company’s results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on the company’s consolidated financial position. While the company believes that it has valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and the company may incur material judgments or enter into material settlements of claims. In addition to the matters described below, the company remains subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on the company’s operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, the company may be exposed to significant litigation concerning the scope of the company’s and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations. General litigation On July 31, 2015, Davita Healthcare Partners, Inc. filed suit against Baxter Healthcare Corporation in the District Court of the State of Colorado regarding an ongoing commercial dispute relating to the provision of peritoneal dialysis products. A bench trial concluded in third quarter 2016 and the parties are awaiting the court’s decision. In November 2016, a purported antitrust class action complaint seeking monetary and injunctive relief was filed in the United States District Court for the Northern District of Illinois. The complaint alleges a conspiracy among manufacturers of IV solutions to restrict output and affect pricing in connection with a shortage of such solutions. Similar parallel actions subsequently were filed. In January 2017, a single consolidated complaint covering these matters was filed in the Northern District of Illinois. The company filed a motion to dismiss the consolidated complaint in February 2017. In April 2017, the company became aware of a criminal investigation by the U.S. Department of Justice, Antitrust Division and a federal grand jury in the United States District Court for the Eastern District of Pennsylvania. The company and an employee received subpoenas seeking production of documents and testimony regarding the manufacturing, selling, pricing and shortages of IV solutions and containers (including saline solutions and certain other injectable medicines sold by the company) and communications with competitors regarding the same. The company is cooperating with the investigation. As previously disclosed, the New York Attorney General has requested that Baxter provide information regarding business practices in the IV saline industry. The company is cooperating with the New York Attorney General. Other In December 2016, the company received a civil investigative demand from the Commercial Litigation Branch of the United States Department of Justice primarily relating to contingent discount arrangements for, and other promotion of, the company’s TISSEEL and ARTIS products. The company is cooperating in this matter.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
SEGMENT INFORMATION	14 SEGMENT INFORMATION Baxter’s two segments are strategic businesses that are managed separately because each business develops, manufactures and markets distinct products and services. The segments and a description of their products and services are as follows: The Renal The Hospital Products The company uses income from continuing operations before net interest expense, income tax expense, depreciation and amortization expense (Segment EBITDA), on a segment basis to make resource allocation decisions and assess the ongoing performance of the company’s business segments. Intersegment sales are eliminated in consolidation. Certain items are maintained at Corporate and are not allocated to a segment. They primarily include most of the company’s debt and cash and equivalents and related net interest expense, foreign exchange fluctuations (principally relating to intercompany receivables, payables and loans denominated in a foreign currency) and the majority of the foreign currency hedging activities, corporate headquarters costs, stock compensation expense, nonstrategic investments and related income and expense, certain employee benefit plan costs as well as certain nonrecurring gains, losses, and other charges (such as business optimization, integration and separation-related costs, and asset impairments). Financial information for the company’s segments is as follows. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Net sales Renal $ 968 $ 965 $ 1,864 $ 1,863 Hospital Products 1,637 1,620 3,216 3,097 Total net sales $ 2,605 $ 2,585 $ 5,080 $ 4,960 EBITDA Renal $ 224 $ 158 $ 423 $ 280 Hospital Products 604 576 1,168 1,085 Total segment EBITDA $ 828 $ 734 $ 1,591 $ 1,365 The following is a reconciliation of segment EBITDA to income from continuing operations before income taxes per the condensed consolidated statements of income. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Total segment EBITDA $ 828 $ 734 $ 1,591 $ 1,365 Reconciling items Depreciation and amortization (184 ) (206 ) (378 ) (395 ) Stock compensation (28 ) (32 ) (46 ) (54 ) Net interest expense (13 ) (11 ) (27 ) (39 ) Restructuring charges, net (16 ) (103 ) (19 ) (107 ) Venezuela deconsolidation (33 ) — (33 ) — Net realized gains on Baxalta Retained Shares transactions — 1,148 — 4,387 Net loss on debt extinguishment — — — (101 ) Other Corporate items (248 ) (312 ) (454 ) (509 ) Income from continuing operations before income taxes $ 306 $ 1,218 $ 634 $ 4,547

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	15. SUBSEQUENT EVENTS On July 27, 2017, Baxter completed the acquisition of Claris Injectables Limited (Claris), a wholly owned subsidiary of Claris Lifesciences Limited, for total consideration of approximately $625 million. Through the acquisition, Baxter added capabilities in production of essential generic injectable medicines, such as anesthesia and analgesics, renal, anti-infectives and critical care in a variety of presentations including bags, vials and ampoules. As the acquisition of Claris was completed after June 30, 2017, Baxter’s condensed consolidated financial statements do not include the financial condition or the operating results of Claris in any of the periods presented herein. At the time of issuance of the company’s condensed consolidated financial statements as of and for the three and six months ended June 30, 2017, the initial accounting for the acquisition of Claris, including the purchase price allocation, was yet to be completed.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (the company or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2016 (2016 Annual Report). In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the interim periods. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the interim period are not necessarily indicative of the results of operations to be expected for the full year. Certain reclassifications have been made to conform the prior period condensed consolidated statements to the current period presentation. Accounting for Venezuelan Operations Currency restrictions enacted in Venezuela require Baxter to obtain approval from the Venezuelan government to exchange Venezuelan bolivars for U.S. dollars and require such exchange to be made at the official exchange rate established by the government. In the first quarter of 2016, the Venezuelan government moved from the three-tier exchange rate system to a two-tiered exchange rate system and the official rate for food and medicine imports was adjusted from 6.3 to 10 bolivars per U.S. dollar. Due to a recent decline in transactions settled at the official rate or the secondary rate and limitations on the company’s ability to repatriate funds generated by its Venezuela operations, the company concluded in the second quarter that it no longer meets the accounting criteria for control over its business in Venezuela and the company deconsolidated its Venezuelan operations on June 30, 2017. As a result of deconsolidating the Venezuelan operations, the company recorded a pre-tax charge of $33 million in other expense (income), net in the second quarter of 2017. This charge included the write-off of the company’s investment in its Venezuelan operations, related unrealized translation adjustments and elimination of intercompany amounts. Beginning in the third quarter of 2017, the company will no longer include the results of its Venezuelan business in its consolidated financial statements.
New Accounting Standards	New accounting standards Recently issued accounting standards not yet adopted In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which amends ASC 715, Compensation – Retirement Benefits, to require employers that present a measure of operating income in their statements of earnings to include only the service cost component of net periodic postretirement benefit cost in operating expenses. The service cost component of net periodic postretirement benefit cost should be presented in the same operating expense line items as other employee compensation costs arising from services rendered during the period. The other components of net benefit cost, including interest costs, expected return on assets, amortization of prior service cost/credit, and settlement and curtailment effects, are to be included separately and outside of any subtotal of operating income. The company intends to adopt the standard effective January 1, 2018. This guidance will impact the presentation of the company’s consolidated statements of income with no impact on net income. Upon adoption of the standard on January 1, 2018, operating income for the three and six months ended June 30, 2017, will be recast to increase $8 million and $17 million, respectively, with a corresponding increase in other expense (income), net. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which amends the existing accounting standards for revenue recognition. ASU No. 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. ASU No. 2014-09 will be effective for the company beginning on January 1, 2018. The standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The company has completed an assessment of the new standard and is currently executing its detailed implementation plan and developing processes for gathering information for required disclosures. Based on the work performed to date, the company does not expect the adoption of the new standard to have a material impact on the consolidated financial statements. The company expects to adopt the standard using the modified retrospective method. Recently adopted accounting pronouncements As of January 1, 2017, the company adopted on a prospective basis ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation – Stock Compensation. The updated guidance requires all tax effects related to share-based payments to be recorded in income tax expense in the consolidated statement of income. Previous guidance required that tax effects of deductions in excess of share-based compensation costs (windfall tax benefits) be recorded in additional paid-in capital, and tax deficiencies be recorded in additional paid-in capital to the extent of previously recognized windfall tax benefits, with the remainder recorded in income tax expense. The new guidance also requires the cash flows resulting from windfall tax benefits to be reported as operating activities in the consolidated statement of cash flows, rather than the previous requirement to present windfall tax benefits as an inflow from financing activities and an outflow from operating activities. As a result of the adoption, net income and operating cash flow for the three and six months ended June 30, 2017, increased by approximately $13 million and $30 million, respectively. The prior periods have not been restated and therefore, windfall tax benefits of $12 million and $27 million, respectively, for the three and six months ended June 30, 2016, were not included in net income and were included as an inflow from financing activities and an outflow from operating activities in the condensed consolidated statement of cash flows. In 2016, the company adopted ASU No. 2016-15, Statement of Cash Flows (Topic 230). The guidance requires that the cash payments for debt prepayment or debt extinguishment costs be classified as cash outflows for financing activities. As a result of the adoption, the company recast certain debt repayments and debt extinguishment costs from operating to financing activities which resulted in an increase to operating cash flow and a decrease in financing cash flows of $33 million for the six months ended June 30, 2016. The adoption of this guidance did not impact the company’s condensed consolidated statements of income, condensed consolidated statements of comprehensive income or condensed consolidated balance sheets.

SEPARATION OF BAXALTA INCORPO24

SEPARATION OF BAXALTA INCORPORATED (Tables)	6 Months Ended
	Jun. 30, 2017
Discontinued Operations And Disposal Groups [Abstract]
Summary of Discontinued Operations	Following is a summary of the operating results of Baxalta, which have been reflected as discontinued operations for the three and six months ended June 30, 2017 and 2016. The assets and liabilities have been classified as held for disposition as of June 30, 2017 and December 31, 2016. Three months ended June 30, Six months ended June 30, (in millions) 2017 2016 2017 2016 Major classes of line items constituting income from discontinued operations before income taxes Net sales $ 2 $ 56 $ 6 $ 120 Cost of sales (1 ) (56 ) (5 ) (115 ) Marketing and administrative expenses — — (1 ) (20 ) Research and development expenses — — — — Other income and expense items that are not major — — — — Income (loss) from discontinued operations before income taxes 1 — — (15 ) Gain on disposal of discontinued operations — — — 17 Income tax expense — — — 9 Income (loss) from discontinued operations, net of tax $ 1 $ — $ — $ (7 ) June 30, December 31, (in millions) 2017 2016 Carrying amounts of major classes of assets included as part of discontinued operations Accounts and other current receivables, net $ 21 $ 48 Property, plant, and equipment, net — 1 Other 1 1 Total assets of the disposal group $ 22 $ 50 Carrying amounts of major classes of liabilities included as part of discontinued operations Accounts payable and accrued liabilities $ 1 $ 3 Total liabilities of the disposal group $ 1 $ 3

SUPPLEMENTAL FINANCIAL INFORM25

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Net Interest Expense	Net interest expense Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Interest expense, net of capitalized interest $ 21 $ 16 $ 40 $ 49 Interest income (8 ) (5 ) (13 ) (10 ) Net interest expense $ 13 $ 11 $ 27 $ 39
Other Expense (Income), Net	Other expense (income), net Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Foreign exchange $ (15 ) $ (3 ) $ (15 ) $ (12 ) Net loss on debt extinguishment — — — 101 Net realized gains on Baxalta Retained Shares transactions — (1,148 ) — (4,387 ) Venezuela deconsolidation 33 — 33 — All other 2 (10 ) 4 (32 ) Other expense (income), net $ 20 $ (1,161 ) $ 22 $ (4,330 )
Inventories	Inventories June 30, December 31, (in millions) 2017 2016 Raw materials $ 329 $ 319 Work in process 141 122 Finished goods 1,055 989 Inventories $ 1,525 $ 1,430
Property, Plant and Equipment, Net	Property, plant and equipment, net June 30, December 31, (in millions) 2017 2016 Property, plant and equipment, at cost $ 9,592 $ 9,162 Accumulated depreciation (5,255 ) (4,873 ) Property, plant and equipment, net $ 4,337 $ 4,289

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Reconciliation of Basic Shares to Diluted Shares	The following table is a reconciliation of basic shares to diluted shares. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Basic shares 544 548 542 548 Effect of dilutive securities 11 5 11 4 Diluted shares 555 553 553 552

GOODWILL AND OTHER INTANGIBLE27

GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	The following is a reconciliation of goodwill by business segment. (in millions) Renal Hospital Products Total Balance as of December 31, 2016 $ 397 $ 2,198 $ 2,595 Additions 5 2 7 Currency translation adjustments 22 122 144 Balance as of June 30, 2017 $ 424 $ 2,322 $ 2,746
Other Intangible Assets, Net	The following is a summary of the company’s other intangible assets. (in millions) Developed technology, including patents Other amortized intangible assets Indefinite-lived intangible assets Total June 30, 2017 Gross other intangible assets $ 1,802 $ 408 $ 32 $ 2,242 Accumulated amortization (940 ) (193 ) — (1,133 ) Other intangible assets, net $ 862 $ 215 $ 32 $ 1,109 December 31, 2016 Gross other intangible assets $ 1,690 $ 384 $ 57 $ 2,131 Accumulated amortization (855 ) (165 ) — (1,020 ) Other intangible assets, net $ 835 $ 219 $ 57 $ 1,111

BUSINESS OPTIMIZATION CHARGES (

BUSINESS OPTIMIZATION CHARGES (Tables)	6 Months Ended
	Jun. 30, 2017
Restructuring And Related Activities [Abstract]
Business Optimization Charges	During the three and six months ended June 30, 2017 and 2016, the company recorded the following charges related to business optimization programs. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Restructuring charges, net $ 16 $ 103 $ 19 $ 107 Costs to implement business optimization programs 16 15 37 19 Gambro integration costs — 7 — 14 Accelerated depreciation 3 14 8 14 Total business optimization charges $ 35 $ 139 $ 64 $ 154
Components of Restructuring Charges	During the three and six months ended June 30, 2017 and 2016, the company recorded the following restructuring charges. Three months ended June 30, 2017 (in millions) COGS SGA R&D Total Employee termination costs $ 4 $ 3 $ — $ 7 Contract termination costs — 4 — 4 Asset impairments 5 — — 5 Total restructuring charges $ 9 $ 7 $ — $ 16 Three months ended June 30, 2016 (in millions) COGS SGA R&D Total Employee termination costs $ 18 $ 9 $ 13 $ 40 Contract termination costs 12 2 14 28 Asset impairments 22 — 13 35 Total restructuring charges $ 52 $ 11 $ 40 $ 103 Six months ended June 30, 2017 (in millions) COGS SGA R&D Total Employee termination costs $ 14 $ 9 $ — $ 23 Contract termination costs — 5 — 5 Asset impairments 5 — — 5 Reserve adjustments (7 ) (5 ) (2 ) (14 ) Total restructuring charges $ 12 $ 9 $ (2 ) $ 19 Six months ended June 30, 2016 (in millions) COGS SGA R&D Total Employee termination costs $ 31 $ 10 $ 14 $ 55 Contract termination costs 12 2 14 28 Asset impairments 22 — 13 35 Reserve adjustments (1 ) (8 ) (2 ) (11 ) Total restructuring charges $ 64 $ 4 $ 39 $ 107
Summary of Cash Activity in Reserves related to Business Optimization Initiatives	The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives. (in millions) Reserves as of December 31, 2016 $ 164 Charges 28 Reserve adjustments (14 ) Utilization (80 ) CTA 14 Reserves as of June 30, 2017 $ 112

DEBT, FINANCIAL INSTRUMENTS A29

DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Financial Instruments And Fair Value Measurements [Abstract]
Summary of Activity Relating to Securitization Arrangement	The following is a summary of the activity relating to the company’s securitization arrangement in Japan. Three months ended June 30, Six months ended June 30, (in millions) 2017 2016 2017 2016 Sold receivables at beginning of period $ 61 $ 85 $ 68 $ 81 Proceeds from sales of receivables 67 93 129 197 Cash collections (remitted to the owners of the receivables) (66 ) (121 ) (137 ) (228 ) Effect of currency exchange rate changes 1 5 3 12 Sold receivables at end of period $ 63 $ 62 $ 63 $ 62
Summary of Gains and Losses on Derivative Instruments	The following tables summarize the income statement locations and gains and losses on the company’s derivative instruments for the three months ended June 30, 2017 and 2016. Gain (loss) recognized in OCI Location of gain (loss) Gain (loss) reclassified from AOCI into income (in millions) 2017 2016 in income statement 2017 2016 Cash flow hedges Interest rate contracts $ (3 ) $ — Net interest expense $ — $ — Foreign exchange contracts (5 ) (7 ) Cost of sales (3 ) (2 ) Net investment hedge (31 ) — Other expense (income), net — — Total $ (39 ) $ (7 ) $ (3 ) $ (2 ) Gain (loss) recognized in income (in millions) Location of gain (loss) in income statement 2017 2016 Fair value hedges Interest rate contracts Net interest expense $ 1 $ 4 Undesignated derivative instruments Foreign exchange contracts Other expense (income), net $ (4 ) $ (11 ) The following tables summarize the income statement locations and gains and losses on the company’s derivative instruments for the six months ended June 30, 2017 and 2016. Gain (loss) recognized in OCI Location of gain (loss) Gain (loss) reclassified from AOCI into income (in millions) 2017 2016 in income statement 2017 2016 Cash flow hedges Interest rate contracts $ (3 ) $ — Other expense (income), net $ — $ 4 Foreign exchange contracts (13 ) (11 ) Cost of sales (1 ) (1 ) Net investment hedge (31 ) — Other expense (income), net — — Total $ (47 ) $ (11 ) $ (1 ) $ 3 Gain (loss) recognized in income (in millions) Location of gain (loss) in income statement 2017 2016 Fair value hedges Interest rate contracts Net interest expense $ — $ 26 Undesignated derivative instruments Foreign exchange contracts Other expense (income), net $ (4 ) $ (5 )
Classification and Fair Value Amounts of Derivative Instruments	The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of June 30, 2017. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other long-term assets $ 7 Other long- term liabilities $ — Foreign exchange contracts Prepaid expenses and other 11 Accounts payable and accrued liabilities 1 Foreign exchange contracts Other long-term assets 3 Other long- term liabilities — Total derivative instruments designated as hedges $ 21 $ 1 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other $ — Accounts payable and accrued liabilities $ 1 Total derivative instruments $ 21 $ 2 The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2016. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other long-term assets $ 7 Other long- term liabilities $ — Foreign exchange contracts Prepaid expenses and other 22 Accounts payable and accrued liabilities 1 Total derivative instruments designated as hedges $ 29 $ 1 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other $ 1 Accounts payable and accrued liabilities $ 2 Total derivative instruments $ 30 $ 3
Derivative Positions Presented on Net Basis	The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty. June 30, 2017 December 31, 2016 (in millions) Asset Liability Asset Liability Gross amounts recognized in the consolidated balance sheet $ 21 $ 2 $ 30 $ 3 Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet (2 ) (2 ) (3 ) (3 ) Total $ 19 $ — $ 27 $ —
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheets. Basis of fair value measurement (in millions) Balance as of June 30, 2017 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Foreign currency hedges $ 14 $ — $ 14 $ — Interest rate hedges 7 — 7 — Available-for-sale securities 10 10 — — Total assets $ 31 $ 10 $ 21 $ — Liabilities Foreign currency hedges $ 2 $ — $ 2 $ — Contingent payments related to acquisitions 10 — — 10 Total liabilities $ 12 $ — $ 2 $ 10 Basis of fair value measurement (in millions) Balance as of December 31, 2016 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Foreign currency hedges $ 23 $ — $ 23 $ — Interest rate hedges 7 — 7 — Available-for-sale securities 9 9 — — Total assets $ 39 $ 9 $ 30 $ — Liabilities Foreign currency hedges $ 3 $ — $ 3 $ — Contingent payments related to acquisitions 19 — — 19 Total liabilities $ 22 $ — $ 3 $ 19
Investments in Available-For-Sale Equity Securities	The following table provides information relating to the company’s investments in available-for-sale equity securities. (in millions) Amortized cost Unrealized gains Unrealized losses Fair value June 30, 2017 $ 9 $ 2 $ 1 $ 10 December 31, 2016 $ 13 $ — $ 4 $ 9
Book Values and Fair Values of Financial Instruments	the following table provides the values recognized in the condensed consolidated balance sheets and the approximate fair values as of June 30, 2017 and December 31, 2016. Book values Approximate fair values (in millions) 2017 2016 2017 2016 Assets Investments $ 41 $ 31 $ 41 $ 31 Liabilities Current maturities of long-term debt and lease obligations $ 3 $ 3 $ 3 $ 3 Long-term debt and lease obligations 3,454 2,779 3,494 2,756
Summarization of Bases Used to Measure Fair Value of Financial Instruments	The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of June 30, 2017 and December 31, 2016. Basis of fair value measurement (in millions) Balance as of June 30, 2017 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Investments $ 41 $ — $ — $ 41 Total assets $ 41 $ — $ — $ 41 Liabilities Current maturities of long-term debt and lease obligations $ 3 $ — $ 3 $ — Long-term debt and lease obligations 3,494 — 3,494 — Total liabilities $ 3,497 $ — $ 3,497 $ — Basis of fair value measurement (in millions) Balance as of December 31, 2016 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Investments $ 31 $ — $ — $ 31 Total assets $ 31 $ — $ — $ 31 Liabilities Current maturities of long-term debt and lease obligations $ 3 $ — $ 3 $ — Long-term debt and lease obligations 2,756 — 2,756 — Total liabilities $ 2,759 $ — $ 2,759 $ —

RETIREMENT AND OTHER BENEFIT 30

RETIREMENT AND OTHER BENEFIT PROGRAMS (Tables)	6 Months Ended
	Jun. 30, 2017
Compensation And Retirement Disclosure [Abstract]
Net Periodic Benefit Cost Relating to Pension and Other Postemployment Benefit Plans	The following is a summary of net periodic benefit cost relating to the company’s pension and other postemployment benefit (OPEB) plans. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Pension benefits Service cost $ 23 $ 24 $ 45 $ 47 Interest cost 45 46 90 92 Expected return on plan assets (73 ) (76 ) (145 ) (151 ) Amortization of net losses and other deferred amounts 41 38 81 75 Net periodic pension benefit cost $ 36 $ 32 $ 71 $ 63 OPEB Service cost $ — $ 1 $ — $ 2 Interest cost 2 2 4 4 Amortization of net loss and prior service credit (7 ) (4 ) (13 ) (8 ) Net periodic OPEB cost $ (5 ) $ (1 ) $ (9 ) $ (2 )

ACCUMULATED OTHER COMPREHENSI31

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Summary of Changes in AOCI by Component	The following table is a net-of-tax summary of the changes in AOCI by component for the six months ended June 30, 2017 and 2016. (in millions) CTA Pension and other employee benefits Hedging activities Available- for-sale securities Total Gains (losses) Balance as of December 31, 2016 $ (3,438 ) $ (1,161 ) $ 3 $ 40 $ (4,556 ) Other comprehensive income before reclassifications 320 (8 ) (11 ) — 301 Amounts reclassified from AOCI (a) 29 46 1 3 79 Net other comprehensive income (loss) 349 38 (10 ) 3 380 Balance as of June 30, 2017 $ (3,089 ) $ (1,123 ) $ (7 ) $ 43 $ (4,176 ) (in millions) CTA Pension and other employee benefits Hedging activities Available- for-sale- securities Total Gains (losses) Balance as of December 31, 2015 $ (3,191 ) $ (1,064 ) $ 7 $ 4,472 $ 224 Other comprehensive income before reclassifications (26 ) (7 ) (9 ) 105 63 Amounts reclassified from AOCI (a) — 47 (2 ) (4,536 ) (4,491 ) Net other comprehensive income (loss) (26 ) 40 (11 ) (4,431 ) (4,428 ) Balance as of June 30, 2016 $ (3,217 ) $ (1,024 ) $ (4 ) $ 41 $ (4,204 ) (a) See table below for details about these reclassifications.
Summary of Reclassification from AOCI to Net Income	The following is a summary of the amounts reclassified from AOCI to net income during the three and six months ended June 30, 2017 and 2016. Amounts reclassified from AOCI (a) (in millions) Three months ended June 30, 2017 Six months ended June 30, 2017 Location of impact in income statement Translation adjustments Loss on Venezuela deconsolidation $ (29 ) $ (29 ) Other expense (income), net (29 ) (29 ) Total before tax — — Tax expense $ (29 ) $ (29 ) Net of tax Amortization of pension and other employee benefits items Actuarial losses and other (b) $ (34 ) $ (68 ) (34 ) (68 ) Total before tax 11 22 Tax benefit $ (23 ) $ (46 ) Net of tax Losses on hedging activities Foreign exchange contracts $ (3 ) $ (1 ) Cost of sales (3 ) (1 ) Total before tax 1 — Tax benefit $ (2 ) $ (1 ) Net of tax Available-for-sale-securities Other-than-temporary impairment of equity securities $ — $ (4 ) Other expense (income), net — (4 ) Total before tax — 1 Tax benefit — (3 ) Net of tax Total reclassification for the period $ (54 ) $ (79 ) Total net of tax Amounts reclassified from AOCI (a) (in millions) Three months ended June 30, 2016 Six months ended June 30, 2016 Location of impact in income statement Amortization of pension and other employee benefits items Actuarial losses and other (b) $ (34 ) $ (67 ) (34 ) (67 ) Total before tax 9 20 Tax benefit $ (25 ) $ (47 ) Net of tax Gains (losses) on hedging activities Interest rate contracts $ — $ 4 Other expense (income), net Foreign exchange contracts (2 ) (1 ) Cost of sales (2 ) 3 Total before tax 1 (1 ) Tax benefit (expense) $ (1 ) $ 2 Net of tax Available-for-sale-securities Gains on sale of equity securities $ 1,148 $ 4,536 Other expense (income), net 1,148 4,536 Total before tax — — Tax expense 1,148 4,536 Net of tax Total reclassification for the period $ 1,122 $ 4,491 Total net of tax (a) Amounts in parentheses indicate reductions to net income. (b) These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 10.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Information	Financial information for the company’s segments is as follows. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Net sales Renal $ 968 $ 965 $ 1,864 $ 1,863 Hospital Products 1,637 1,620 3,216 3,097 Total net sales $ 2,605 $ 2,585 $ 5,080 $ 4,960 EBITDA Renal $ 224 $ 158 $ 423 $ 280 Hospital Products 604 576 1,168 1,085 Total segment EBITDA $ 828 $ 734 $ 1,591 $ 1,365
EBITDA to Income from Continuing Operations Reconciliation	The following is a reconciliation of segment EBITDA to income from continuing operations before income taxes per the condensed consolidated statements of income. Three months ended Six months ended June 30, June 30, (in millions) 2017 2016 2017 2016 Total segment EBITDA $ 828 $ 734 $ 1,591 $ 1,365 Reconciling items Depreciation and amortization (184 ) (206 ) (378 ) (395 ) Stock compensation (28 ) (32 ) (46 ) (54 ) Net interest expense (13 ) (11 ) (27 ) (39 ) Restructuring charges, net (16 ) (103 ) (19 ) (107 ) Venezuela deconsolidation (33 ) — (33 ) — Net realized gains on Baxalta Retained Shares transactions — 1,148 — 4,387 Net loss on debt extinguishment — — — (101 ) Other Corporate items (248 ) (312 ) (454 ) (509 ) Income from continuing operations before income taxes $ 306 $ 1,218 $ 634 $ 4,547

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016VEF / $	Dec. 31, 2015VEF / $
Basis Of Presentation [Line Items]
Pre-tax charge recorded due to deconsolidation	$ (33)		$ (33)
ASU 2017-07 Not Yet Adopted, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
Basis Of Presentation [Line Items]
Increase in operating income	8		17
Increase in other expense (income), net	8		17
ASU 2016-09, Improvements to Employee Share-Based Payment Accounting
Basis Of Presentation [Line Items]
Increase in net income	13		30
Increase in operating cash flow	$ 13		$ 30
Windfall tax benefits		$ 12		$ 27
ASU 2016-15, Statement of Cash Flows
Basis Of Presentation [Line Items]
Decrease in financing cash flows				$ (33)
Devaluation of Venezuelan Bolivar
Basis Of Presentation [Line Items]
Description of change in exchange rate system			In the first quarter of 2016, the Venezuelan government moved from the three-tier exchange rate system to a two-tiered exchange rate system and the official rate for food and medicine imports was adjusted from 6.3 to 10 bolivars per U.S. dollar.
Official rate for food and medicine imports per U.S. dollar | VEF / $					10	6.3
Description of control and deconsolidation			Due to a recent decline in transactions settled at the official rate or the secondary rate and limitations on the company’s ability to repatriate funds generated by its Venezuela operations, the company concluded in the second quarter that it no longer meets the accounting criteria for control over its business in Venezuela and the company deconsolidated its Venezuelan operations on June 30, 2017.
Devaluation of Venezuelan Bolivar | Other Expense (Income)
Basis Of Presentation [Line Items]
Pre-tax charge recorded due to deconsolidation			$ 33

Separation of Baxalta Incorpo34

Separation of Baxalta Incorporated - Additional Information (Detail) - USD ($) $ in Millions	Jul. 02, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts payable and accrued liabilities		$ 2,471		$ 2,471		$ 2,612
Cash flows from operations – discontinued operations				(49)	$ 8
Transition Services Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Reduction in marketing and administrative expense		16	$ 26	$ 36	53
Transition Services Agreement | Minimum | Manufacturing and supply agreement (MSA)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
The termination of service period				5 years
Transition Services Agreement | Maximum | Manufacturing and supply agreement (MSA)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
The termination of service period				10 years
Spinoff | Transition Services Agreement | Manufacturing and supply agreement (MSA)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales		6	14	$ 12	25
Cost of sales		50	48	98	92
Baxalta Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash flows from operations – discontinued operations				(49)	(8)
Baxalta Inc | Discontinued Operations, Held-for-disposition
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts payable and accrued liabilities		21		21		$ 47
Net sales		2	56	6	120
Cost of sales		$ 1	$ 56	$ 5	$ 115
Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of outstanding common stock distributed	80.50%
Percentage of common stock retained	19.50%
Common stock, shares outstanding	131,902,719
Record date for distribution	Jun. 17, 2015
Shares issued for each share held	1

Summary of Operating Results Wh

Summary of Operating Results Which Have Been Reflected As Discontinued Operations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations, net of tax	$ 1			$ (7)
Baxalta Inc | Discontinued Operations, Held-for-disposition
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	2	$ 56	$ 6	120
Cost of sales	(1)	$ (56)	(5)	(115)
Marketing and administrative expenses			$ (1)	(20)
Income (loss) from discontinued operations before income taxes	1			(15)
Gain on disposal of discontinued operations				17
Income tax expense				9
Income (loss) from discontinued operations, net of tax	$ 1			$ (7)

Summary of Assets and Liabiliti

Summary of Assets and Liabilities Classified As Held For Disposition (Detail) - Baxalta Inc - Discontinued Operations, Held-for-disposition - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts and other current receivables, net	$ 21	$ 48
Property, plant, and equipment, net		1
Other	1	1
Total assets of the disposal group	22	50
Accounts payable and accrued liabilities	1	3
Total liabilities of the disposal group	$ 1	$ 3

Net Interest Expense (Detail)

Net Interest Expense (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Interest Income Expense Net
Interest expense, net of capitalized interest	$ 21	$ 16	$ 40	$ 49
Interest income	(8)	(5)	(13)	(10)
Net interest expense	$ 13	$ 11	$ 27	$ 39

Other Expense (Income), Net (De

Other Expense (Income), Net (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Other Expense (Income), net
Foreign exchange	$ (15)	$ (3)	$ (15)	$ (12)
Net loss on debt extinguishment				101
Net realized gains on Baxalta Retained Shares transactions		(1,148)		(4,387)
Venezuela deconsolidation	33		33
All other	2	(10)	4	(32)
Other expense (income), net	$ 20	$ (1,161)	$ 22	$ (4,330)

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 329	$ 319
Work in process	141	122
Finished goods	1,055	989
Inventories	$ 1,525	$ 1,430

Property, Plant and Equipment,

Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment, Net
Property, plant and equipment, at cost	$ 9,592	$ 9,162
Accumulated depreciation	(5,255)	(4,873)
Property, plant and equipment, net	$ 4,337	$ 4,289

Reconciliation of Basic Shares

Reconciliation of Basic Shares to Diluted Shares (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Reconciliation of Basic Shares to Diluted Shares
Basic shares	544	548	542	548
Effect of dilutive securities	11	5	11	4
Diluted shares	555	553	553	552

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Nov. 30, 2016	Jul. 31, 2012
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from computation of EPS	6,000,000	9,000,000	4,000,000	14,000,000
Stock repurchase program, authorized amount						$ 2,000,000,000
Stock repurchase program, additional authorized amount					$ 1,500,000,000
Share repurchases			1,800,000	0
Value of share repurchases			$ 95,000,000
Remaining value available under stock repurchase programs	$ 1,600,000,000		$ 1,600,000,000

Acquisitions and Other Arrang43

Acquisitions and Other Arrangements - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Apr. 30, 2017	Jun. 30, 2017	Mar. 31, 2016
Celerity Pharmaceutical LLC | Clindamycin Saline
Acquisitions And Collaborations [Line Items]
Payment to acquire the rights		$ 10
Estimated economic life		12 years
Celerity Pharmaceutical LLC | Vancomycin injection
Acquisitions And Collaborations [Line Items]
Payment to acquire the rights			$ 23
Estimated economic life			12 years
Wound Care Technologies Inc
Acquisitions And Collaborations [Line Items]
Payment to acquire the rights	$ 8
Estimated economic life	8 years
Purchase price allocation, amortizable intangible asset	$ 8

Goodwill (Detail)

Goodwill (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
Goodwill [Line Items]
Goodwill, beginning balance	$ 2,595
Additions	7
Currency translation adjustments	144
Goodwill, ending balance	2,746
Renal
Goodwill [Line Items]
Goodwill, beginning balance	397
Additions	5
Currency translation adjustments	22
Goodwill, ending balance	424
Hospital Products
Goodwill [Line Items]
Goodwill, beginning balance	2,198
Additions	2
Currency translation adjustments	122
Goodwill, ending balance	$ 2,322

Goodwill and Other Intangible45

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill And Other Intangible Asset [Line Items]
Accumulated goodwill impairment losses	$ 0		$ 0
Intangible asset amortization expense	$ 36	$ 42	$ 74	$ 82
Impairment of intangible assets		51
Developed Technology Asset | Hospital Products
Goodwill And Other Intangible Asset [Line Items]
Impairment of intangible assets		$ 41

Other Intangible Assets, Net (D

Other Intangible Assets, Net (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	$ 2,242	$ 2,131
Accumulated amortization	(1,133)	(1,020)
Other intangible assets, net	1,109	1,111
Developed technology, including patents
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	1,802	1,690
Accumulated amortization	(940)	(855)
Other intangible assets, net	862	835
Other amortized intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	408	384
Accumulated amortization	(193)	(165)
Other intangible assets, net	215	219
Indefinite-lived intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Other intangible assets	$ 32	$ 57

Business Optimization Charges -

Business Optimization Charges - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Restructuring And Related Activities [Abstract]
Cumulative pretax costs incurred	$ 474		$ 474
Expected additional pretax costs	335		335
Expected capital expenditures	90		$ 90
Restructuring charges non-cash percentage			5.00%
Costs to implement business optimization programs	16	$ 15	$ 37	$ 19
Accelerated depreciation	$ 3	$ 14	$ 8	$ 14
Percentage of restructuring reserves related to employee terminatino costs	80.00%		80.00%

Business Optimization Charges48

Business Optimization Charges (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Restructuring And Related Activities [Abstract]
Restructuring charges	$ 16	$ 103	$ 19	$ 107
Costs to implement business optimization programs	16	15	37	19
Gambro integration costs		7		14
Accelerated depreciation	3	14	8	14
Total business optimization charges	$ 35	$ 139	$ 64	$ 154

Components of Restructuring Cha

Components of Restructuring Charges (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 16	$ 103	$ 19	$ 107
Reserve adjustments			(14)	(11)
Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7	40	23	55
Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4	28	5	28
Asset impairments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5	35	5	35
Cost of Goods Sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	9	52	12	64
Reserve adjustments			(7)	(1)
Cost of Goods Sold | Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4	18	14	31
Cost of Goods Sold | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		12		12
Cost of Goods Sold | Asset impairments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5	22	5	22
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7	11	9	4
Reserve adjustments			(5)	(8)
Selling, General and Administrative Expenses | Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3	9	9	10
Selling, General and Administrative Expenses | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 4	2	5	2
Research and Development Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges		40	(2)	39
Reserve adjustments			$ (2)	(2)
Research and Development Expenses | Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		13		14
Research and Development Expenses | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		14		14
Research and Development Expenses | Asset impairments
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 13		$ 13

Summary of Cash Activity and Re

Summary of Cash Activity and Reserve Adjustments (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Restructuring Cost and Reserve [Line Items]
Charges	$ 16	$ 103	$ 19	$ 107
Reserve adjustments			(14)	$ (11)
Severance and Other Employee Related Costs
Restructuring Cost and Reserve [Line Items]
Reserve, beginning balance			164
Charges			28
Reserve adjustments			(14)
Utilization			(80)
CTA			14
Reserve, ending balance	$ 112		$ 112

Debt, Financial Instruments a51

Debt, Financial Instruments and Fair Value Measurements - Additional Information (Detail) € in Millions	Mar. 16, 2016USD ($)	Jan. 27, 2016USD ($)	Mar. 31, 2016USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	May 31, 2017EUR (€)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Debt and Financial Instruments [Line Items]
Net realized gains on the Baxalta Retained Share transactions						$ 1,148,000,000		$ 4,387,000,000
Loss on extinguishment of debt								101,000,000
Maximum length of time hedge in cash flow hedge							17 months
Terminated interest rate contract			$ 765,000,000
Gain on termination of interest rate contract			$ 34,000,000
Terminated fair value hedges							$ 0
Loss on hedged item in fair value hedge				$ 1,000,000		4,000,000		26,000,000
Deferred, net after-tax losses on derivative instruments							(5,000,000)
Cash and equivalents				3,817,000,000		2,630,000,000	3,817,000,000	2,630,000,000		$ 2,801,000,000	$ 2,213,000,000
Other-than-temporary impairment losses related to investments					$ 4,000,000
Significant Other Observable Inputs (Level 2)
Debt and Financial Instruments [Line Items]
Money market funds, at carrying value				1,000,000,000			1,000,000,000			1,000,000,000
Significant Unobservable Inputs (Level 3)
Debt and Financial Instruments [Line Items]
Change in fair value of contingent payment related to achievement of certain sales-based milestones							8,000,000
Designated as Hedging Instrument
Debt and Financial Instruments [Line Items]
Derivative notional amount				0		$ 0	0	0
Not Designated as Hedging Instrument
Debt and Financial Instruments [Line Items]
Derivative notional amount				756,000,000			756,000,000			822,000,000
Net investment hedge
Debt and Financial Instruments [Line Items]
Accumulated pre-tax unrealized translation losses in AOCI related to euro-denominated senior notes				31,000,000			31,000,000
Foreign exchange contract
Debt and Financial Instruments [Line Items]
Derivative notional amount				673,000,000			673,000,000			561,000,000
Interest rate contract
Debt and Financial Instruments [Line Items]
Derivative notional amount				0			0			0
Interest rate contract | Fair value hedges
Debt and Financial Instruments [Line Items]
Derivative notional amount				200,000,000			200,000,000			$ 200,000,000
Greece, Spain, Portugal and Italy
Debt and Financial Instruments [Line Items]
Total accounts receivable from certain countries with liquidity issues				$ 148,000,000			$ 148,000,000
Domestic Line of Credit
Debt and Financial Instruments [Line Items]
Drawing		$ 1,450,000,000
Line of Credit Facility Amount Outstanding		$ 1,800,000,000
Net realized gains on the Baxalta Retained Share transactions								1,250,000,000
1.30% due May 2025
Debt and Financial Instruments [Line Items]
Senior notes | €									€ 600
Senior notes, coupon rates									1.30%
Higher rate of debt maturity periods							May 2,025
Debt Tender Offer
Debt and Financial Instruments [Line Items]
Tender offer date							Mar. 16, 2016
Net realized gains on the Baxalta Retained Share transactions								2,000,000,000
Principal amount of notes exchanged for Retained Share	$ 2,200,000,000
Loss on extinguishment of debt								$ 101,000,000
Debt Tender Offer | 0.950% notes due 2016
Debt and Financial Instruments [Line Items]
Senior notes, coupon rates	0.95%
Higher rate of debt maturity periods							May 2,016
Debt Tender Offer | 5.900% Senior Unsecured Notes due 2016
Debt and Financial Instruments [Line Items]
Senior notes, coupon rates	5.90%
Higher rate of debt maturity periods							August 2,016
Debt Tender Offer | 1.850% Notes due 2017
Debt and Financial Instruments [Line Items]
Senior notes, coupon rates	1.85%
Higher rate of debt maturity periods							January 2,017
Debt Tender Offer | 5.375% notes due 2018
Debt and Financial Instruments [Line Items]
Senior notes, coupon rates	5.375%
Higher rate of debt maturity periods							May 2,018
Debt Tender Offer | 1.850% notes due 2018
Debt and Financial Instruments [Line Items]
Senior notes, coupon rates	1.85%
Higher rate of debt maturity periods							June 2,018
Debt Tender Offer | 4.500% notes due 2019
Debt and Financial Instruments [Line Items]
Senior notes, coupon rates	4.50%
Higher rate of debt maturity periods							August 2,019
Debt Tender Offer | 4.250% notes due 2020
Debt and Financial Instruments [Line Items]
Senior notes, coupon rates	4.25%
Higher rate of debt maturity periods							February 2,020

Summary of Activity Relating to

Summary of Activity Relating to Securitization Arrangement (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Sold receivables at beginning of period	$ 61	$ 85	$ 68	$ 81
Proceeds from sales of receivables	67	93	129	197
Cash collections (remitted to the owners of the receivables)	(66)	(121)	(137)	(228)
Effect of currency exchange rate changes	1	5	3	12
Sold receivables at end of period	$ 63	$ 62	$ 63	$ 62

Summary of Gains and Losses on

Summary of Gains and Losses on Derivative Instruments (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	$ (39)	$ (7)	$ (47)	$ (11)
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax	(3)	(2)	(1)	3
Gain (loss) recognized in income, fair value hedges	(1)	(4)		(26)
Other expense (income), net | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, undesignated derivative instruments	(4)	(11)	(4)	(5)
Cash Flow Hedges | Interest rate contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	(3)		(3)
Cash Flow Hedges | Interest rate contract | Other expense (income), net
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax				4
Cash Flow Hedges | Foreign exchange contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	(5)	(7)	(13)	(11)
Cash Flow Hedges | Foreign exchange contract | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax	(3)	(2)	(1)	(1)
Net investment hedge
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	(31)		$ (31)
Fair value hedges | Net Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, fair value hedges	$ 1	$ 4		$ 26

Classification and Fair Value A

Classification and Fair Value Amounts of Derivative Instruments (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	$ 21	$ 30
Derivative liability, fair value	2	3
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	21	29
Derivative liability, fair value	1	1
Designated as Hedging Instrument | Interest rate contract | Other Long-Term Assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	7	7
Designated as Hedging Instrument | Foreign exchange contract | Other Long-Term Assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	3
Designated as Hedging Instrument | Foreign exchange contract | Prepaid expenses and other
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	11	22
Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	1	1
Not Designated as Hedging Instrument | Foreign exchange contract | Prepaid expenses and other
Derivatives, Fair Value [Line Items]
Derivative asset, fair value		1
Not Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	$ 1	$ 2

Derivative Positions Presented

Derivative Positions Presented On Net Basis (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Gross amounts recognized in the consolidated balance sheet, Asset	$ 21	$ 30
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Asset	(2)	(3)
Total, Asset	19	27
Gross amounts recognized in the consolidated balance sheet, Liability	2	3
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Liability	$ (2)	$ (3)

Summary of Financial Assets and

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedges, assets at fair value	$ 14	$ 23
Interest rate hedges, assets at fair value	7	7
Available-for-sale securities	10	9
Total assets	31	39
Foreign currency hedges, liabilities at fair value	2	3
Contingent payments related to acquisitions	10	19
Total liabilities	12	22
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	10	9
Total assets	10	9
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedges, assets at fair value	14	23
Interest rate hedges, assets at fair value	7	7
Total assets	21	30
Foreign currency hedges, liabilities at fair value	2	3
Total liabilities	2	3
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent payments related to acquisitions	10	19
Total liabilities	$ 10	$ 19

Available-for-Sale Equity Secur

Available-for-Sale Equity Securities (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Amortized cost	$ 9	$ 13
Unrealized gains	2
Unrealized losses	1	4
Fair value	$ 10	$ 9

Book Values and Fair Values of

Book Values and Fair Values of Financial Instruments (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Book Values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Investments	$ 41	$ 31
Current maturities of long-term debt and lease obligations	3	3
Long-term debt and lease obligations	3,454	2,779
Approximate fair values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Investments	41	31
Current maturities of long-term debt and lease obligations	3	3
Long-term debt and lease obligations	$ 3,494	$ 2,756

Summarization of Bases Used to

Summarization of Bases Used to Measure Fair Value of Financial Instruments (Detail) - Approximate fair values - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments	$ 41	$ 31
Total assets	41	31
Current maturities of long-term debt and lease obligations	3	3
Long-term debt and lease obligations	3,494	2,756
Total liabilities	3,497	2,759
Significant other observable inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Current maturities of long-term debt and lease obligations	3	3
Long-term debt and lease obligations	3,494	2,756
Total liabilities	3,497	2,759
Significant unobservable inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments	41	31
Total assets	$ 41	$ 31

Stock Compensation - Additional

Stock Compensation - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense		$ 28	$ 32	$ 46	$ 54
Stock Options granted	5.4
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards Granted	0.7
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards Granted	0.6
Marketing and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense allocation percentage		70.00%	70.00%	70.00%	70.00%

Net Periodic Benefit Cost Relat

Net Periodic Benefit Cost Relating to Pension and Other Postemployment Benefit Plans (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Pension benefits
Net periodic benefit cost
Service cost	$ 23	$ 24	$ 45	$ 47
Interest cost	45	46	90	92
Expected return on plan assets	(73)	(76)	(145)	(151)
Amortization of net losses and other deferred amounts	41	38	81	75
Net periodic benefit cost	36	32	71	63
OPEB
Net periodic benefit cost
Service cost		1		2
Interest cost	2	2	4	4
Amortization of net loss and prior service credit	(7)	(4)	(13)	(8)
Net periodic benefit cost	$ (5)	$ (1)	$ (9)	$ (2)

Summary of Changes in AOCI by C

Summary of Changes in AOCI by Component (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance				$ 8,280
Other comprehensive income before reclassifications				301	$ 63
Amounts reclassified from AOCI	[1]			79	(4,491)
Total other comprehensive income (loss), net of tax		$ 242	$ (1,169)	380	(4,428)
Ending Balance		9,165		9,165
CTA
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance				(3,438)	(3,191)
Other comprehensive income before reclassifications				320	(26)
Amounts reclassified from AOCI	[1]			29
Total other comprehensive income (loss), net of tax				349	(26)
Ending Balance		(3,089)	(3,217)	(3,089)	(3,217)
Pension and other employee benefits
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance				(1,161)	(1,064)
Other comprehensive income before reclassifications				(8)	(7)
Amounts reclassified from AOCI	[1]			46	47
Total other comprehensive income (loss), net of tax				38	40
Ending Balance		(1,123)	(1,024)	(1,123)	(1,024)
Hedging activities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance				3	7
Other comprehensive income before reclassifications				(11)	(9)
Amounts reclassified from AOCI	[1]			1	(2)
Total other comprehensive income (loss), net of tax				(10)	(11)
Ending Balance		(7)	(4)	(7)	(4)
Available-for-sale securities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance				40	4,472
Other comprehensive income before reclassifications					105
Amounts reclassified from AOCI	[1]			3	(4,536)
Total other comprehensive income (loss), net of tax				3	(4,431)
Ending Balance		43	41	43	41
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance				(4,556)	224
Ending Balance		$ (4,176)	$ (4,204)	$ (4,176)	$ (4,204)
[1]	See table below for details about these reclassifications.

Summary of Amounts Reclassifica

Summary of Amounts Reclassification from AOCI to Net Income (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other expense (income), net		$ (20)	$ 1,161	$ (22)	$ 4,330
Cost of sales		1,475	1,613	2,908	3,023
Reclassifications, Total before tax		306	1,218	634	4,547
Reclassifications, Tax expense (benefit)		(42)	(6)	(97)	52
Net income		265	1,212	537	4,592
Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net income	[1]	(54)	1,122	(79)	4,491
Translation adjustments | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassifications, Total before tax	[1]	(29)		(29)
Net income	[1]	(29)		(29)
Translation adjustments | Loss on Venezuela deconsolidation | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other expense (income), net	[1]	(29)		(29)
Amortization of pension and other employee benefits items | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Actuarial losses and other	[1],[2]	(34)	(34)	(68)	(67)
Reclassifications, Total before tax	[1]	(34)	(34)	(68)	(67)
Reclassifications, Tax expense (benefit)	[1]	11	9	22	20
Net income	[1]	(23)	(25)	(46)	(47)
Gains (losses) on hedging activities | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassifications, Total before tax	[1]	(3)	(2)	(1)	3
Reclassifications, Tax expense (benefit)	[1]	1	1		(1)
Net income	[1]	(2)	(1)	(1)	2
Gains (losses) on hedging activities | Foreign exchange contract | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales	[1]	$ (3)	(2)	(1)	(1)
Gains (losses) on hedging activities | Interest rate contracts | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other expense (income), net	[1]				4
Other-than-temporary impairment of equity securities | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other expense (income), net	[1]			(4)
Available-for-sale-securities | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassifications, Total before tax	[1]		1,148	(4)	4,536
Reclassifications, Tax expense (benefit)	[1]			1
Net income	[1]		1,148	$ (3)	4,536
Gains on sale of equity securities | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other expense (income), net	[1]		$ 1,148		$ 4,536
[1]	Amounts in parentheses indicate reductions to net income.
[2]	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 10.

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Effective income tax rate	13.70%	0.50%	15.30%	(1.10%)
Effective income tax rate stock compensation program with tax windfall benefits percentage points			4.70%

Legal Proceedings - Additional

Legal Proceedings - Additional Information (Detail)	Jun. 30, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
Litigation reserve	$ 19,000,000
Litigation related receivables	$ 0

Segment Information - Additiona

Segment Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017Segment
Segment Reporting [Abstract]
Number of segments	2

Segment Information (Detail)

Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Net sales	$ 2,605	$ 2,585	$ 5,080	$ 4,960
Segment EBITDA	828	734	1,591	1,365
Renal
Segment Reporting Information [Line Items]
Net sales	968	965	1,864	1,863
Segment EBITDA	224	158	423	280
Hospital Products
Segment Reporting Information [Line Items]
Net sales	1,637	1,620	3,216	3,097
Segment EBITDA	$ 604	$ 576	$ 1,168	$ 1,085

EBITDA to Income from Continuin

EBITDA to Income from Continuing Operations Reconciliation (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting [Abstract]
Total segment EBITDA	$ 828	$ 734	$ 1,591	$ 1,365
Reconciling items
Depreciation and amortization	(184)	(206)	(378)	(395)
Stock compensation	(28)	(32)	(46)	(54)
Net interest expense	(13)	(11)	(27)	(39)
Restructuring charges, net	(16)	(103)	(19)	(107)
Venezuela deconsolidation	(33)		(33)
Net realized gains on Baxalta Retained Shares transactions		1,148		4,387
Net loss on debt extinguishment				(101)
Other Corporate items	(248)	(312)	(454)	(509)
Income from continuing operations before income taxes	$ 306	$ 1,218	$ 634	$ 4,547

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Millions	Jul. 27, 2017USD ($)
Claris Injectables Limited
Subsequent Event [Line Items]
Total consideration	$ 625